XTX Topco Ltd Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

XTX Topco Ltd bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,102 shares of the company's stock, valued at approximately $329,000.

Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Krystal Biotech during the 4th quarter valued at about $34,391,000. Raymond James Financial Inc. purchased a new position in Krystal Biotech during the fourth quarter valued at approximately $15,989,000. Franklin Resources Inc. boosted its position in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares during the period. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Up 1.0 %

Krystal Biotech stock traded up $1.74 during mid-day trading on Monday, reaching $169.80. 89,365 shares of the company's stock traded hands, compared to its average volume of 279,947. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a 50 day moving average of $176.37 and a two-hundred day moving average of $171.56. The company has a market cap of $4.91 billion, a price-to-earnings ratio of 56.79 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the firm earned $0.30 EPS. The firm's revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KRYS. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. HC Wainwright increased their target price on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital upped their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Finally, Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Krystal Biotech has an average rating of "Buy" and a consensus price target of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).